A5079946853- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Head and Neck Surgical Oncology
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Bioinformatics and Genomic Networks
- Thyroid Cancer Diagnosis and Treatment
- Ear and Head Tumors
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Oral health in cancer treatment
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Genetics, Bioinformatics, and Biomedical Research
- Oral and Maxillofacial Pathology
- Tumors and Oncological Cases
- Tracheal and airway disorders
- Renal cell carcinoma treatment
- Sinusitis and nasal conditions
National Cancer Center Hospital East
2016-2025
Japan Cancer Society
2025
National Cancer Centre Japan
2023
Jikei University School of Medicine
1970-2016
American Society for Gastrointestinal Endoscopy
2010
Saitama Medical University Hospital
2009
Kobe University Hospital
2009
Meikai University
2002
Abstract Background To determine the safety, preliminary efficacy, pharmacokinetics, and immunogenicity of a single cycle RM-1929 photoimmunotherapy, an anti-EGFR antibody cetuximab conjugated with light-activatable dye (IRDye ® 700DX), in Japanese patients recurrent head neck squamous cell carcinoma (rHNSCC). Methods Patients received fixed dose (640 mg/m 2 ) light treatment (50 J/cm for superficial illumination; 100 fiber diffuser length interstitial illumination). Safety, tumor response...
We investigated the tolerability of cetuximab plus radiotherapy in Japanese patients with untreated locally advanced squamous cell carcinoma head and neck.Patients epidermal growth factor receptor-expressing neck received (400 mg/m(2) initial dose then 250 weekly) for 7 weeks concomitant boost (weeks 2-7: once daily [1.8 Gy] 3.6 weeks, twice Gy morning 1.5 afternoon] 2.4 weeks). The primary endpoint was treatment completion rate (the treated completing ≥70% planned full within 2 over...
The current standard of care for post-operative high-risk squamous cell carcinoma the head and neck is concurrent chemoradiotherapy with a 3-weekly cycle cisplatin (3W-CDDP/RT). In previous pivotal trials, complete delivery rate three cycles radiation therapy was only ~60%. Here, we evaluated feasibility safety 3W-CDDP/RT in Japanese population.The study enrolled patients. High-risk factors were microscopically incomplete resection, extracapsular extension two or more lymph node metastases....
Background In the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, toxicity of is sometimes considerable and requires frequent dose interruptions modifications. Recently, planned drug holidays have been proposed as a means avoiding severe adverse events (AEs). Methods We retrospectively reviewed medical records to compare efficacy safety RR-DTC who underwent...
Abstract Background Induction chemotherapy (IC) in locally advanced squamous cell carcinoma of the head and neck (LA‐SCCHN) often compromises compliance with subsequent chemoradiotherapy (CRT), which negatively affects outcomes. Here, we assessed combination paclitaxel (PTX), carboplatin (CBDCA), cetuximab (Cmab) as IC for unresectable LA‐SCCHN. Methods consisted weekly CBDCA area under plasma concentration‐time curve = 1.5, PTX 80 mg/m 2 Cmab an initial dose 400 followed by 250 8 weeks....
Abstract The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence–driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics deliver effective drugs patients. Concurrently, studies assessing residual disease–based precision medicine resectable solid tumors, including CIRCULATE-Japan, are ongoing. substantial data generated by these platforms stored within...
<title>Abstract</title> Background <italic>BRAF</italic> V600E mutation is a significant therapeutic target for thyroid cancer, including anaplastic cancer (ATC). Although targeted therapy this requires genomic testing in Japan, turnaround time (TAT) often unacceptably long, especially certain conditions, such as ATC, which one of the most aggressive cancers. Here, we evaluated concordance between immunohistochemistry (IHC) with relatively short TAT few days and cancer. Methods...
PURPOSE The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS We assessed the clinical value ctDNA using data from 2,187 patients advanced solid tumors enrolled SCRUM-Japan MONSTAR-SCREEN-1, nationwide cancer genome screening project, which examined longitudinally collected blood samples and (UMIN 000036749). RESULTS Among 667 both baseline results, 51 (7.6%) had...
2613 Background: Prior clinical trials have established the effectiveness of poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) or immune checkpoint (ICI) monotherapy in patients with cancer characterized by mutations homologous recombination repair (HRR) genes. This trial aims to evaluate efficacy and safety PARPi PD-1 HRR gene-mutated solid tumors previously treated ICIs. Methods: IMAGENE is an open-label phase II basket study evaluating niraparib cancers that shown resistance one more...
2629 Background: Calcitonin gene-related peptide (CGRP), a neuropeptide associated with pain perception, has emerged as therapeutic target for migraine. Recent studies have reported that the CGRP pathway is suppression of anti-tumor immunity and poor prognosis in patients (pts) solid tumors via induction CD8+ T cell exhaustion by sensory nerves. However, clinical significance genes oncology including impact efficacy immune checkpoint inhibitors (ICIs) remains elusive. Herein, we evaluated...
6007 Background: No standard treatment exists for unresectable locally advanced (LA) or recurrent/metastatic (R/M) salivary gland cancer (SGC). Previous findings suggest that combined androgen blockade (CAB) provides promising clinical activity in patients with receptor (AR)-positive SGC. However, no AR-targeted drug is currently approved This multi-center phase 2 study investigated two approaches LA R/M SGC: darolutamide monotherapy followed by the combination of and goserelin. In phase,...
6063 Background: In 2024, the Head and Neck Cancer International Group (HNCIG) newly defined imaging-detected pathological extranodal extension (iENE/pENE). We previously reported utility of iENE in induction chemotherapy followed by definitive chemoradiotherapy (Onaga R, et al. ASCO Annual Meeting, 2024). However, significance surgically treated head neck squamous cell carcinoma (HNSCC) remains unclear, particularly high-risk populations with positive pENE. aimed to investigate prognostic...
Abstract Background The development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis use immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy tropomyosin receptor kinase inhibitors against neurotrophic tyrosine (NTRK) fusion gene-positive advanced solid tumors have been established as second tumor-agnostic treatment, making it...
For the treatment of patients with T4b nasal and sinonasal malignancies, definitive chemoradiotherapy was contraindicated due to risk brain damage blindness. However, combination chemotherapy docetaxel, cisplatin S-1 is well tolerated effective. We conducted a retrospective analysis evaluate efficacy feasibility induction using followed by proton beam therapy concurrent cisplatin. Thirteen treated were analyzed. Docetaxel, consisted 60–70 mg/m2/day docetaxel on day 1, 70 1 60–80 days 1–14....